De rol van veroudering van het immuunsysteem bij het melanoom.
Recruiting
- Conditions
- Metastatic melanoma.
- Registration Number
- NL-OMON22761
- Lead Sponsor
- MCG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
1.Pathologically proven melanoma, metastasized
2.No prior systemic anti-tumour treatment
Exclusion Criteria
1.Without pathologically proven melanoma
2.Treated with immune-modulating drugs
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the frequencies and differentiation status of CD4 and CD8 T cell populations (Tnaive, TCM, TEM, TEMRA) in young (18-50) and old (> 65) treatment naive metastasized melanoma patients at baseline. In addition, the frequencies and differentiation of Treg in these two age groups will be assessed. We compare this with data from two age-matched groups healthy controls to distinguish age-factors from melanoma-factors.
- Secondary Outcome Measures
Name Time Method -To study the presence of markers of the immune risk phenotype in patients (e.g. CD4/CD8-ratio, CMV-status). <br /><br>-To study markers of immune senescence (e.g. CD27, CD28) and exhaustion (e.g. PD1, CTLA-4).<br /><br>-Furthermore, this study increases our understanding of the pathophysiology of behaviour and development of melanoma in elderly and young patients.